Trials / Terminated
TerminatedNCT02701634
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids as part of first-line therapy for cGVHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ENTO | Tablets administered orally |
| DRUG | Placebo | Tablets administered orally |
Timeline
- Start date
- 2016-05-27
- Primary completion
- 2017-12-19
- Completion
- 2018-03-06
- First posted
- 2016-03-08
- Last updated
- 2018-12-26
- Results posted
- 2018-12-26
Locations
30 sites across 7 countries: United States, Canada, France, Germany, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02701634. Inclusion in this directory is not an endorsement.